Company Overview - Blade Air Mobility, Inc. is a technology-powered air mobility platform that provides air transportation and logistics for hospitals across the United States, being one of the largest transporters of human organs for transplant [2] - The company offers helicopter and fixed-wing services primarily in the Northeast United States and Southern Europe, operating an asset-light model with exclusive passenger terminal infrastructure and proprietary technologies [2] Upcoming Events - Rob Wiesenthal, the CEO of Blade, will present at the Ladenburg Thalmann Technology Innovation Expo 25 on May 21, 2025, at 3:00 PM ET, with a webcast available for investors [1] Business Model and Technology - Blade's model is designed to facilitate a seamless transition from traditional helicopters and fixed-wing aircraft to Electric Vertical Aircraft (EVA or eVTOL), aiming for lower-cost air mobility that is both quiet and emission-free [2]

Core Insights - 22nd Century Group, Inc. is focused on nicotine harm reduction and offers smokers choices regarding their nicotine consumption [3][4] - The company will present a corporate update at the Emerging Growth Conference on May 21, 2025, led by CEO Larry Firestone [1][2] Company Overview - 22nd Century Group is a pioneering company in the tobacco industry, enabling smokers to control their nicotine intake [3] - The flagship product, VLN cigarettes, contains 95% less nicotine than traditional cigarettes and aims to reduce overall nicotine consumption [4][6] Product and Technology - VLN cigarettes are designed to provide an authentic smoking experience while allowing smokers to make informed choices about nicotine levels [4] - The company utilizes patented technologies to create reduced nicotine tobacco blends, ensuring high flavor and yield with significantly lower nicotine content [6] Manufacturing Capabilities - The company operates a 60,000 square foot facility in Mocksville, North Carolina, capable of producing over 45 million cartons of combusted tobacco products annually, with room for expansion [5] - The facility also provides turnkey contract manufacturing for other tobacco brands both domestically and internationally [5]

Core Points - SalMar will present its results for the first quarter of 2025 on May 20, 2025, at 08:00 CEST [1] - The presentation will be held at Hotel Continental in Oslo, featuring CEO Frode Arntsen and CFO Ulrik Steinvik [1] - An English webcast recording will be available from 10:00 CEST on the company's website [1] Additional Information - Following the main presentation, there will be two group presentations: one in Norwegian at 12:00 CEST and another in English at 15:15 CEST [2] - Results will be accessible from 06:30 CET on the company's homepage and the Oslo Stock Exchange's page [2] - For further inquiries, contact Håkon Husby, Head of Investor Relations, via phone or email [2]

One-Year Data Show Lasting Reductions in Glucocorticoid Doses and Improvements in Clinical Outcomes with CRENESSITY™ (crinecerfont) in Pediatric Patients with Classic Congenital Adrenal Hyperplasia SAN DIEGO, May 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present new data from the Phase 3 CAHtalyst™ Pediatric study showing lasting reductions in glucocorticoid doses in pediatric patients with classic congenital adrenal hyperplasia who received CRENESSITY™ (cr ...

Core Viewpoint - Howmet Aerospace Inc. will participate in Bernstein's 41st Annual Strategic Decisions Conference on May 30, 2025, where CEO John C. Plant will present [1] Group 1: Company Overview - Howmet Aerospace Inc. is a leading global provider of advanced engineered solutions for the aerospace and transportation industries [2] - The company's primary businesses include jet engine components, aerospace fastening systems, and airframe structural components [2] - Howmet Aerospace holds approximately 1,170 granted patents, focusing on technologies that enable lighter, more fuel-efficient aircraft and commercial trucks [2] Group 2: Future Announcements - Howmet Aerospace plans to disseminate future announcements regarding company developments and financial performance through its website [3]

Merus (MRUS) 2025 Conference May 15, 2025 11:40 AM ET Speaker0 Good morning. Welcome to the final, day of the Bank of America Healthcare Conference. I'm Tazeen Ahmad. I'm one of the senior SMID biotech analysts at the firm. It's our pleasure to have with us, our next presenting company, Maris. Presenting from Maris this morning is CEO Bill Lindenberg. Bill, good morning. Thanks for flying to Las Vegas for us. Speaker1 Happy to be here. And let me also extend a great deal of thanks to you, to Zeen, and the e ...

Streaming giant Netflix Inc NFLX shared an impressive milestone for its ad-supported plan at its upfront presentation to advertisers, along with highlighting upcoming content that includes bets on live content and reality television.Ad-Supported Plan Shines: Fresh off its recent quarterly financial results that beat Street estimates, Netflix and its shareholders may have more reasons to celebrate.The company announced its ad-supported plan, which launched in 2022, has hit 94 million monthly active users glo ...

NORCROSS, Ga., May 15, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended March 31, 2025. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, stated "This quarter, we remained laser-focused on advancing additional analyses for belapectin. I was extremely encouraged by the feedback we received last week at the ...

REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that preliminary clinical data from the Phase I COVALENT-103 trial of BMF-500 in adults with acute leukemia (AL) were selected for a poster presentation at the European Hematology Association (EHA) 2025 Congress, taking place June 12–15 in Milan, Italy. The presentation will highlight emerging safety, pharmacokinetics/pharmacodynamics ...

Core Insights - Kura Oncology and Kyowa Kirin announced that clinical data from the KOMET-007 trial of ziftomenib will be presented at the EHA2025 Congress, highlighting its potential as a treatment for acute myeloid leukemia (AML) patients with specific mutations [1][2][3] Company Overview - Kura Oncology is a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, with ziftomenib being the first investigational therapy to receive Breakthrough Therapy Designation from the FDA for relapsed or refractory NPM1-m AML [6][7] - Kyowa Kirin is a Japan-based global specialty pharmaceutical company with over 70 years of experience in drug discovery and biotechnology innovation, focusing on high unmet medical needs in various therapeutic areas [8] Clinical Trial Details - The KOMET-007 trial is a multicenter Phase 1 study evaluating ziftomenib in combination with standard care treatments for newly diagnosed AML patients with NPM1-m or KMT2A-r mutations [2][3] - The upcoming oral presentation will include updated data from the Phase 1a and Phase 1b portions of the trial, specifically focusing on the combination of ziftomenib with the 7+3 chemotherapy regimen [2][4] Future Developments - The results from the KOMET-007 trial are expected to support the initiation of a pivotal Phase 3 trial, KOMET-017, aimed at further evaluating the combination treatment for AML patients [3][5] - Kura and Kyowa Kirin are also conducting additional clinical trials to assess ziftomenib in various combinations for both newly diagnosed and relapsed/refractory AML patients [7]